Skip to main content
. Author manuscript; available in PMC: 2023 Feb 2.
Published in final edited form as: Clin Cancer Res. 2022 Aug 2;28(15):3242–3247. doi: 10.1158/1078-0432.CCR-21-3867

Figure 2. Progression-Free (A) and Overall Survival (B) by Disease Subtype.

Figure 2.

(A) Progression-free survival for patients with chronic lymphocytic leukemia [median 8.9 (95%CI: 3.9–16.1) months] and non-Hodgkin lymphoma [median 2.7 (95%CI: 0.7–5.4) months]. (B) Estimated 2-year overall survival was 73.7% (95%CI:44.1–89.2%) and 27.8% (95%CI:10.1–48.9%) for CLL and NHL patients, respectively.